Department of Clinical Pharmacy and Pharmacotherapy, Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Germany (R.E., A.R., M.H., M.P., H.B., R.A.B.).
Institute of Clinical Chemistry and Laboratory Medicine (S.A.H., M.F.), University Medical Center Hamburg-Eppendorf, Germany.
Arterioscler Thromb Vasc Biol. 2022 Apr;42(4):444-461. doi: 10.1161/ATVBAHA.121.317380. Epub 2022 Mar 3.
TP (thromboxane A receptor) plays an eminent role in the pathophysiology of endothelial dysfunction and cardiovascular disease. Moreover, its expression is reported to increase in the intimal layer of blood vessels of cardiovascular high-risk individuals. Yet it is unknown, whether TP upregulation per se has the potential to affect the homeostasis of the vascular endothelium.
We combined global transcriptome analysis, lipid mediator profiling, functional cell analyses, and in vivo angiogenesis assays to study the effects of endothelial TP overexpression or knockdown/knockout on the angiogenic capacity of endothelial cells in vitro and in vivo.
Here we report that endothelial TP expression induces COX-2 (cyclooxygenase-2) in a G- and G-dependent manner, thereby promoting its own activation via the auto/paracrine release of TP agonists, such as PGH (prostaglandin H) or prostaglandin F but not TxA (thromboxane A). TP overexpression induces endothelial cell tension and aberrant cell morphology, affects focal adhesion dynamics, and inhibits the angiogenic capacity of human endothelial cells in vitro and in vivo, whereas TP knockdown or endothelial-specific TP knockout exerts opposing effects. Consequently, this TP-dependent feedback loop is disrupted by pharmacological TP or COX-2 inhibition and by genetic reconstitution of PGH-metabolizing prostacyclin synthase even in the absence of functional prostacyclin receptor expression.
Our work uncovers a TP-driven COX-2-dependent feedback loop and important effector mechanisms that directly link TP upregulation to angiostatic TP signaling in endothelial cells. By these previously unrecognized mechanisms, pathological endothelial upregulation of the TP could directly foster endothelial dysfunction, microvascular rarefaction, and systemic hypertension even in the absence of exogenous sources of TP agonists.
TP(血栓烷 A 受体)在血管内皮功能障碍和心血管疾病的病理生理学中起着重要作用。此外,据报道,其表达在心血管高危人群血管内膜层增加。然而,尚不清楚 TP 的上调本身是否有可能影响血管内皮的内稳态。
我们结合了全转录组分析、脂质介质分析、功能细胞分析和体内血管生成测定,研究了内皮 TP 过表达或敲低/敲除对体外和体内内皮细胞血管生成能力的影响。
我们报告称,内皮 TP 表达以 G-和 G-依赖性方式诱导 COX-2(环氧化酶-2),从而通过自身/旁分泌释放 TP 激动剂(如 PGH(前列腺素 H)或前列腺素 F)来促进自身的激活,但不是 TxA(血栓烷 A)。TP 过表达诱导内皮细胞张力和异常细胞形态,影响焦点粘附动力学,并抑制体外和体内人内皮细胞的血管生成能力,而 TP 敲低或内皮特异性 TP 敲除则产生相反的效果。因此,这种依赖于 TP 的反馈回路被药理学 TP 或 COX-2 抑制以及 PGH 代谢的前列环素合酶的遗传重建所破坏,即使在没有功能性前列环素受体表达的情况下也是如此。
我们的工作揭示了一个由 TP 驱动的 COX-2 依赖性反馈回路和重要的效应机制,该机制直接将 TP 的上调与内皮细胞中的抗血管生成 TP 信号联系起来。通过这些以前未被认识的机制,病理上内皮细胞对 TP 的上调可直接促进内皮功能障碍、微血管稀疏和全身性高血压,即使在外源 TP 激动剂的来源不存在的情况下也是如此。